HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ: AKBA ) with a Buy and maintains $6 price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.